Treatment of Advanced Breast Cancer with 2 α-Methyl-dihydrotestosterone Propionate

Open Access
Publisher Website
Google Scholar
Abstract
The activity of 2 α-methyl-dihydrotestosterone propionate, was evaluated on 20 women with advanced breast cancer. The age of the patients ranged from 31 to 74 years; the compound was administered i.m. 100 mg 3 times a week, over a period of time ranging from 2 weeks to 8 months. An objective improvement was obtained in 6 patients; the mean duration of the improvement was of 5.8 months (with a maximum of 8 months). In 9 patients the lesions remained unchanged, while in 5 there was a progression of the disease during the treatment. The neoplastic lesions of breast, skin and lymph nodes appeared to be much more responsive to the treatment than the osseous and visceral lesions. The highest percentage of improvement was obtained in early postmenopausal women. The compound proved to be practically free of virilizing action, one woman only showing a marked virilization. No other notable side effects were observed.